Cryoviva Life Sciences Conferred with Kalam Medal of Excellence in Genomic Innovation at The Next Gene 2026
New Delhi, 10 Oct 2026: Cryoviva Life Sciences has been conferred with the Kalam Medal of Excellence in Genomic Innovation at The Next Gene – India’s BioScience Summit 2026, recognising the company’s continued commitment to innovation and its contribution to the evolving biosciences and genomics ecosystem. The recognition marks an important milestone for Cryoviva Life Sciences as it continues to strengthen its focus on scientific advancement, emerging technologies and solutions aimed at supporting the future of healthcare and life sciences. The award also reflects the collective expertise, passion and research-driven approach of the organisation’s team, which remains focused on exploring new possibilities within genomics and related areas of bioscience. As advancements in genomics increasingly influence preventive healthcare, personalised medicine, diagnostics and biomedical research, Cryoviva Life Sciences continues to build its capabilities around science-led innovation while contributing to greater awareness and adoption of advanced life-science solutions.
Commenting on the recognition, Mr. Vikas Sharma, Chief Operating Officer, Cryoviva Life Sciences, said, “Receiving the Kalam Medal of Excellence in Genomic Innovation is a proud moment for the entire Cryoviva Life Sciences team. This recognition reinforces our belief that meaningful innovation is driven by a combination of scientific excellence, continuous learning and a clear commitment to creating long-term value for the healthcare ecosystem. Genomics is opening new possibilities in the way we understand health, disease and personalised care, and we are committed to contributing responsibly to this rapidly evolving field. I dedicate this recognition to our team whose passion, expertise and relentless pursuit of innovation continue to move us forward.” The honour at The Next Gene 2026 further strengthens Cryoviva Life Sciences’ focus on advancing scientific possibilities and participating actively in conversations shaping the future of biosciences. Going forward, the company aims to continue investing in knowledge, collaboration and innovation while working towards solutions that can contribute to the next phase of genomic science and healthcare advancement.
